Improvement of nocturia symptoms and associated quality of life in patients with Parkinson’s disease treated with foslevodopa/foscarbidopa: results from 2 phase 3 trials
Objective: To assess nocturia over time and its correlation with quality of life (QoL) in patients with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDP/CDP). Background:…Randomized Controlled Trial comparing continuous intrajejunal levodopa infusion and deep brain stimulation for Parkinson’s disease. Cost-effectiveness and cost-utility outcomes of the INVEST study
Objective: To determine the costs of continuous intrajejunal levodopa infusion (CILI) and deep brain stimulation (DBS) for Parkinson’s disease (PD), and to study the cost-effectiveness…Use of levodopa-carbidopa intestinal gel to treat a patient with multiple system atrophy (MSA)
Objective: To describe a case report on the use of Levodopa-carbidopa intestinal gel (LCIG) to treat non-motor symptoms in a patient with multiple system atrophy (MSA) Background: There is no…Social and gender inequity on overall survival and access to deep brain stimulation in Parkinson disease patients in Colombia
Objective: Describe discrepancies on survival and access to DBS in PD in Colombia by gender and affiliation regime. Background: Lower socioeconomic status (SES) has been…Continuity and presence of side effects of continuous subcutaneous apomorphine infusion and levodopa-carbidopa intestinal gel infusion in advanced Parkinson’s disease, in a movement disorder unit in Spain
Objective: To determine the number of patients that maintain infusion therapies (continuous subcutaneous apomorphine infusion (CSAI) and levodopa-carbidopa intestinal gel (LCIG)) as treatment for advanced…Continuous subcutaneous foslevodopa/foscarbidopa: final results from a phase 3, open-label study
Objective: Evaluate safety and efficacy of foslevodopa/foscarbidopa (LDP/CDP) for patients with Parkinson’s disease (PD) in a 52-week, phase 3 study. Background: As PD progresses, patients…Efficacy and safety of adjunctive oral therapy in Parkinson’s disease with motor complications: a systematic review and network meta-analysis
Objective: To review the evidence and compare the efficacy and safety of catechol-O-methyltransferase inhibitors (COMT-Is), dopamine agonists (DAs) and monoamine-oxidase B inhibitors (MAOB-Is) as adjunctive…Beta LFP Power Change After Levodopa Intake in Parkinson’s Disease Patients with Chronic Sensing-Enabled DBS Systems
Objective: To study the relationship between oscillatory beta activity in the subthalamic nucleus (STN) and the intake of dopaminergic medication in a group of Parkinson’s…Continuous subcutaneous levodopa/carbidopa infusion with ND0612 for Parkinson’s disease: Three-year data from the open-label BeyoND study
Objective: To evaluate three-year outcomes from the ND0612 BeyoND study. Background: Investigational ND0612 is in development as a 24-hour continuous, subcutaneous infusion of liquid levodopa/carbidopa…Basal ganglia shape in de novo Parkinson’s disease patients can predict the onset of Levodopa Induced Dyskinesias
Objective: In the current study, we aimed to examine structural MRI data from a large sample of de novo PD patients and to identify potential…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 57
- Next Page »